Review highlights advancements in car-t therapy and emergent strategies to enhance efficacy in solid tumors, suggesting significant clinical potential.
Key Points
CAR-T therapy shows limited success in solid tumors due to tumor microenvironment challenges and T cell persistence issues.
Second- and third-generation CAR-T cells have exhibited restricted efficacy, with ongoing trials exploring next-generation strategies.
Innovative approaches like cytokine-armored CAR-T cells and bispecific T cell engagers are being tested in clinical trials to improve outcomes.
The study identifies the need for new solutions to combat immunosuppression and antigen escape in solid tumor environments.